close 74% of retail investor accounts lose money when trading CFDs with this provider. Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
SearchSearch
Change languageEnglish (International)
Dashboard

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Home・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

10.06 1.41

Strong Buy

Price update 24 Feb 2026, 20:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

9.78

Max

10.77

Key metrics

By Trading Economics

Income

4.1M

-33M

Sales

6.1M

44M

EPS

-2.227

Profit margin

-75.213

Employees

279

EBITDA

1.8M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+66.2% upside

Market Stats

By TradingEconomics

Market Cap

55M

157M

Previous open

8.65

Previous close

10.06

News Sentiment

By Acuity

50%

50%

114 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Feb 2026, 23:07 UTC

Earnings

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

DJ

Read

24 Feb 2026, 23:01 UTC

Earnings

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

DJ

Read

24 Feb 2026, 22:59 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

DJ

Read

24 Feb 2026, 22:42 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

DJ

Read

24 Feb 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

DJ

Read

24 Feb 2026, 23:48 UTC

Earnings

OCBC's Fourth-Quarter Net Profit Rose on Higher Non-Interest Income

DJ

Read

24 Feb 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

DJ

Read

24 Feb 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

DJ

Read

24 Feb 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

DJ

Read

24 Feb 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

DJ

Read

24 Feb 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

24 Feb 2026, 23:16 UTC

Earnings

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

DJ

Read

24 Feb 2026, 23:13 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

DJ

Read

24 Feb 2026, 23:12 UTC

Earnings

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

DJ

Read

24 Feb 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

DJ

Read

24 Feb 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

DJ

Read

24 Feb 2026, 23:08 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

DJ

Read

24 Feb 2026, 23:07 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

DJ

Read

24 Feb 2026, 22:52 UTC

Earnings

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

DJ

Read

24 Feb 2026, 22:46 UTC

Earnings

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

DJ

Read

24 Feb 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

DJ

Read

24 Feb 2026, 22:29 UTC

Earnings

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

DJ

Read

24 Feb 2026, 22:28 UTC

Earnings

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

DJ

Read

24 Feb 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

DJ

Read

24 Feb 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

DJ

Read

24 Feb 2026, 22:25 UTC

Earnings

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

DJ

Read

24 Feb 2026, 22:24 UTC

Earnings

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

DJ

Read

24 Feb 2026, 22:23 UTC

Earnings

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

DJ

Read

24 Feb 2026, 22:22 UTC

Earnings

Woolworths Interim Dividend 45 Australian Cents/Share

DJ

Read

24 Feb 2026, 22:22 UTC

Earnings

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

66.2% upside

12 Months Forecast

Average 16.67 USD  66.2%

High 23 USD

Low 12 USD

Based on 4 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Based on 4 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

114 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,042.27

↓-1.11%

JNJ

Johnson and Johnson

246.2

↑ +0.25%

ABBV

AbbVie Inc

228.42

↓-0.4%

NVS

Novartis AG

166.68

↑ +1.33%

MRK

Merck & Co Inc.

123.89

↑ +0.15%
help-icon Live chat